0001104659-15-044605.txt : 20150610 0001104659-15-044605.hdr.sgml : 20150610 20150610163102 ACCESSION NUMBER: 0001104659-15-044605 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 3 CONFORMED PERIOD OF REPORT: 20150608 ITEM INFORMATION: Other Events ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20150610 DATE AS OF CHANGE: 20150610 FILER: COMPANY DATA: COMPANY CONFORMED NAME: SUPERNUS PHARMACEUTICALS INC CENTRAL INDEX KEY: 0001356576 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 000000000 STATE OF INCORPORATION: DE FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-35518 FILM NUMBER: 15923793 BUSINESS ADDRESS: STREET 1: 1550 E GUDE DR CITY: ROCKVILLE STATE: MD ZIP: 20850 BUSINESS PHONE: 301-838-2500 MAIL ADDRESS: STREET 1: 1550 E GUDE DR CITY: ROCKVILLE STATE: MD ZIP: 20850 8-K 1 a15-13836_18k.htm 8-K

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported): June 8, 2015

 

Supernus Pharmaceuticals, Inc.

(Exact name of registrant as specified in its charter)

 

Delaware

(State or other jurisdiction of
Incorporation)

 

001-35518

 

20-2590184

(Commission File Number)

 

(IRS Employer Identification No.)

 

1550 East Gude Drive, Rockville MD

 

20850

(Address of principal executive offices)

 

(Zip Code)

 

Registrant’s telephone number, including area code:  (301) 838-2500

 

Not Applicable

(Former name or former address, if changed since last report.)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

 

o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

 

 


 

Item 8.01                                           Other Events.

 

On June 8, 2015, Supernus Pharmaceuticals, Inc. (“Supernus” or the “Company”) issued a press release announcing that it will webcast its Investor Day presentation on June 17, 2015.  A copy of this press release is furnished as Exhibit 99.1 hereto and is incorporated herein by reference.

 

Item 9.01                                           Financial Statements and Exhibits.

 

(d)                                 Exhibit

 

The following document is furnished as an Exhibit pursuant to Item 8.01 hereof:

 

Exhibit 99.1 — Press Release Dated June 8, 2015.

 

2


 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

 

 

SUPERNUS PHARMACEUTICALS, INC.

 

 

 

DATED: June 10, 2015

By:

/s/ Gregory S. Patrick

 

 

Gregory S. Patrick

 

 

Vice-President and Chief Financial Officer

 

3


 

EXHIBIT INDEX

 

Number

 

Description

 

 

 

 

 

 

 

99.1

 

Press Release Dated June 8, 2015.

 

Attached

 

4

 EX-99.1 2 a15-13836_1ex99d1.htm EX-99.1

Exhibit 99.1

 

 

Supernus Announces Webcast of Investor Day on June 17, 2015

 

ROCKVILLE, Md., June 8, 2015 — Supernus Pharmaceuticals, Inc. (NASDAQ: SUPN), a specialty pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system diseases, today announced that it will webcast its Investor Day presentation on June 17, 2015.

 

During the meeting, members of Supernus’ senior management team will provide a detailed discussion of the Company’s clinical programs, including efficacy and safety results for completed trials of its two late stage clinical programs, plans for prospective clinical trials, and an assessment of their market opportunity. In addition, several key thought leaders will share their perspectives on the current treatment paradigms, unmet medical needs, and the Company’s clinical development programs.

 

Presentation Date: Wednesday, June 17, 2015
Time: 8:30 a.m. ET to approximately 12:00 p.m. ET
Place: New York Marriott East Side, 525 Lexington Avenue, New York, NY

 

Registration and details are available via the Company’s Investor Day webpage located here.

 

A live webcast of the presentation can be accessed by visiting ‘Events & Presentations’ in the Investors Section on the Company’s website at www.supernus.com. An archived replay of the webcast will be available on the Company’s website.

 

About Supernus Pharmaceuticals, Inc.

 

Supernus Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system diseases. The Company has two marketed products for epilepsy, Oxtellar XR® (extended-release oxcarbazepine) and Trokendi XR® (extended-release topiramate). The Company is also developing several product candidates to address large market opportunities in psychiatry, including SPN-810 for the treatment of impulsive aggression in patients with ADHD in conjunction with standard ADHD treatment and SPN-812 for ADHD.

 

CONTACT:

 

Jack A. Khattar, President and CEO

Gregory S. Patrick, Vice President and CFO

Supernus Pharmaceuticals, Inc.

Tel: (301) 838-2591

 

Or

 

Investor Contact:

Peter Vozzo

Westwicke Partners

Office: (443) 213-0505

Mobile: (443) 377-4767

Email: peter.vozzo@westwicke.com

 

 GRAPHIC 3 g138361mmi001.gif GRAPHIC begin 644 g138361mmi001.gif M1TE&.#EA&@%!`'<`,2'_"TU33T9&24-%.2XP#0````%S4D="`*[.'.D`(?\+ M1T%-34%.3UZ<`(?\+35-/1D9)0T4Y+C`5````"7!(67,```[$```.Q`&5 M*PX;`"'Y!`$``+X`+``````:`4$`A__]___^_]?7YZRPS)&6O)&7O+N]U;KD>_QM_;VTOOZ M[7IA][D:=[C:-_D:GLFUEG/C[;N^UG5] MK)ZCQ>/C[N3HAR4V=7)^@"A:BMNV9PH^7IB'5] MJ^+G?:2L/($,BZ$1GB\F3*%$\",FRI9>/*G;NPUR%9LJ!8F@-E#MY7O`+`'9Q5\-G! MB`6>0#EQH=(E<.E*GDSSL&7+AL\>4C&GA6?/@7;(&`UJQHPL-FJ=S;SZ,&NX M&DZB*+BZ8-LXA1%?WLU;M^_>KG\#W_UZ./#,Q8TK9VTX^?+@@ITKQ]S;8.OH MA"W7VO/9\XXS:GSZ_SP"*@FOR,RQ#T2IH>;E@0BVK.2=6WUV[-E=V[?__KY_ M_-?])V!SS-U7GX'^!4?<@`@6M]]_Z@$(H7O"G<6++-VU$`@C1YC$@'@@HI&$ M$OR]MP1*!0P48&W62:C@<`5.%YEN#E9GXXO&Q7ACCM3A]YIT/F^@F!MFT=$V)8T-KCCC@RX>F5A^*DJ(W)<)ME:; M@!#Z!J298"X8)X!7HF<@A:_Q8DF&@43QY)\^S4!B<@'<=%)[69'Y8HEGKMEH MD!5"&NF".W))GYN4"BFFBUP2RFFDA(*JHIK1\:+D9U6@`>B?'YYDQ14!#O]4 M`$H,U-F?FK=:2IVC%6:9'XX1)OC@HKR&221RV-R,];[G;IK'!GGFQU\0L%4CG2"@Y6&'#-S"$5$@P7##"HNG M<-`^G:%"N8(Q+('+8T*K'YL8JR>`!BNQ)D`!!#QPPA=`*OK%$@\0$,<27(], MG0$&9'K`4:`Q0TE;G-&PP4-7;CG1)^T@"Y9;^>3`"4(*L,3H<13PP`-+K!P`WTMD M#1FN`1C@ATE`'5;`P1I`%J=K2\0F7NYX^[?$['ZL)L?L)SE@,96^9XG``P`:F`S#!A`!Q6IL:(0#\18N"2Y% M(+?[4R>"1YTO^`YA?O"#!6E7MN"]`7D_$8P`#K9!P;Q!`Y`SB6"^T`E6N0\Q M*&3/E00@0A"UIS]?0"$=_T+8P/]M`3`,=>K&8`&B@/7ZH6G-4,#`7J&$T M2.#!%GAPABW081*7`]J'*O<_;45A#^=!3Q'%TX@!8`E+<1LA[0@4``2LT2>U M4XP<3<*&7GQ0@\/JA>!,T@C$"40`(U1>`0>P1Z`(((8H`0H9%I9$2#JI=JX1 M0!P:B2P$A`^/&.L<'09`D#S4T"15(\`&F^@'`H3K@:O)V<`F(4`&%&P+53#) M&:QPDC#ZCP$+\!]*`@&%PJS.DBAI(P4+*)`S+-0B#J+P`8&@RWTJ31;B,(.3-*"7BX@F'<=&D9[!;:`##%M--3C*5F.",Z#!!;;TDVE,XH)>5HZOEH.N3W804F;:!%`,<".I)+95^B`6 MD^A9Z1S!JE+Q:/(>@E"5`0M-SW<=FYC]0I.V M6_BA?@;B`'.&BP$#[84$$"685^C,!4>81""VT`)5A6(&S+6KPO(ZQKX"$"5V M`&QZ)):6/TDU,;&%);Y2["O77O!D/#6M@7L!8`'SY@L^.;%`8KN%QF0I(3XQ M$D]I)>0`L/A3+-8/`5!B,QI]#[5Q8(`&"*`*!CP`FGO*$`LFO(-%T,$%JJK" M)YC;I%9M>*\-PVN'&V82-'CF_SS&#``5J`"))CE)N\WQ[[J2K!\]]R@KEASH M&AL1PD(;NH@``#R$-! M>*$S%K35!9,XKL\6L0CF\O(D?-V"FCELYH]2N`6RP)L*E.0"%_S!SMFZH6". M;+=>)!DYQ/Z4:K>`N#S0:E56*LR1U:4R2M\M`)%V;++[0VRB!K!MT*GOHP.` MH8&Q(!1;<,$,D.`"G\U@PFZ=!$KNBE?H=M0GGIG#0`X1OQ:PH-U$N]@DG2"`Q$U'`(I#Y.+NB\Y^=12A((,K,M;.<\)]Q&?+ M(-,/0_\=<.+B+!`HF)L%,CCNNEV@Q1E8<0N?:`'D@"EK6?'I<1%`.FO?6>,*`#W2=5\,PK`M!OB+(@ MX*!!9AP,OO`"?M?)![^3:FVK::Q;A/$LW9A^/%XDCT=HXQOS+QU-2ZL'+&]` M!%&"SOP]@^.V6NE>=`&\`Z^J,FZX[SS7*YLS%W!9K/7EW6FK3TAK[-=&;>M& M-KZ9(J-IS/[1\@KIT;1UU9QLXZOK,OP1GV-T;&:>/243R9'_T5_.`D8<=\)5 MB.@6=@#F+1S!!:XIQM>]T7:>@7C=P0*N`%"KL6TP!H3%=X'K M$@!+=A*-\4>8Q2,$HG7*URGH$7(&$G8_B%7]Y(0L%2'VQ8$> MT6J!X`)6X&;P%@@M<#];,`GPUR&Z]TNZAQ("I"$PL'\0U1T`I7'=]2.6]G^8 MM"D!H&G,AQ+B="R?,H!]^'6NP7E?_^AYCC=RF.&`4U5BW?0R'QB&AW=XG[%^ M<>=6+&`'6W!<.V,2;M@"KR9K-1A=/P+C05C MS(%"#/9."..%-M)BR4>$)#.!V3<@5`@70H@=W?>!4V4PRSA@LK")UGAX$&8% M_W8$5N`9)?$)L@&`BIAY MA!%Y+15#;B08($7@J,-3*L).[75] MY)9TG&B-H'`$_X:":CA7%_6&)K$`C%"&+K`#C'"&2(`$C+`#.X`&JX@Y:@A[ M:O"*YC8P*_]X$DWG?TXVA..%;,K'*%4"5<:T>TO$A/G1;<`"YB3FXB5SFC6Y6?EZ$?SYSCF@@`U50!3N0EI-@!SW` M=WR',&KP&?`6"DCG=M:(;EPQD+V4+ZLA7@"8CXT''2AD2`+1"=K2!DQS&.9S M'038,7#AB,21D`SHD`C3D(`)7@*!`@L%+IN)$A;@@0-1C==H>&B`!`$W5Y]P M>+Q$!T1'2QX"*#W`/PHS"3IH$G00"-=HC7@9'B47M.@@9MV7=EY':>T21'4`09N9LL MP(8FD2*)X9SX54+PP8&:"1>(965`TBHH<">DIP%Y&5YH5A@:<>`0A>9+R)V'D&`AM M>9I(@`9V,`FGP`BLV((0A9]NIF5NIY&H-%_=&`%$M9KEAH:5B!_ M/#>*=$"*;N<"J.`3)FAXIX"?6Z"`2#,`!T-H([02Q9E4G2"C[X5*&>H:P(4P M#E"KDXD`>_0D+80<-.03N)$NJW&$)Z%V]'(6R[9XSK)2_L.J)^&JW?0`L8I! MLO$ZBX8M)R8M`;`*[,F5GX&"[TDP)6$'.9@JT&82=C!F^HE+-NEO+I`*XD$' M9S`:/&"J;1!9$<.%LH$XQ7DH`\%C)T$'2:5*%C1:XD8@@P4H=(!$6?%]3O(: MT(8=$ZL?R#-&1B1/J3.(3H(H@.FG8>,`"G,!7PICB3$0`I-TZ\DX%_49JO)% MQ`6DINH3^OF2]?^)=Z=HC9L0`'DP`-ST.]"G,M6M89&F%I[:);1M5Z;'X;B/T5K@%F:M)'U/,C4 M,#63.+"3>GFX@RNKH_@'B^[W"6I(CBJX")_`")^0EB?I,U\D;^8JMT>C(B=0 M`.BC30]0`):W+RE:`!K0!CIA`0;Q!H+P!N0UE2?!6G)P/2'4N-#7A(3R!I(; M0@70CT:2=?U$$7>2$,2!`))+N05@N06!N9I+$9_[`"&D$[HCIPI2$)3`GL3[ M&3I*=%N6BCU0I&K):FHI`U$`.=V(=U;@`KSI&8>P$0+Y$2>[<9>G/>/_]H'Z M5!?4![M::1WA1KZP"XWC5"R+4A#E1J`#TT6@`%&!8`?`!B)J4)(MX#.GZ)^> M$5@:(2=:.,`[^6+D*RDJIR62IK[$,F#^LL#AML#CQ+[7]V@(>;(%,03KR8DK MVQTN$`IT`+.;"'^?8`5#NI)$6I*O*`-T<`3R^8J+V@*U4)EUX2LOFED2'&[> M:[[F4D!?P$@;ZVB\@JB*Y2[@ZY?V\KH4HL")(0"JT%!X(I#D%;_?BG2!H$5J M@+?_9JE>?*DRP`!TT()>G(=#X+82*61Z0\'Z8C9P:E`_-AQLX`=S[`<2(`C5 MV0NJR@"-\6<_XAP%"9F0&\=>LL`(P``=&BWH_R*R4MPT(D->',R;'ERCY6@2 MR[N6)AD(B[`#=J`J1\`(>ONN&5+#?JG#)!,U0\(H@AF53*-5#L`W6^$'HG83 M&YNL;Z8PR)P.`(-K.J]NM'4R@7+G,A\=JSFN2S%QJB+<'V>LI-4*L@:S.VB-Z M[8P>N340-\%:LY(Z5(R=[P*%?RS,2]P:%G!>79/0V,:EMLPHM"$02J`D`RJ_ M\JMEEJJ#3HIKR1F0(/^S+"USA732;K,X?+@+:<4A4XU?TRF0Z] MQ*[54#6T04MF`+XCRRGZUL`Y/"AG$KS5"`^P2:@D`$4$UWH$<>'E`+.370(A M"(1&L.$RQZ1T`AH00KZ,`O@50@)@V/$E$`8@V&+<0@B@"B8!!K4ZTFP%<[G`!]=$HW!$W#Q2$#_ MT0GYU1:N]%+SH:H*>0(UU`98XU2K]3T,T&3X=6#(?5K#7#L2ND_?J7G0U%(I MF\R2O-*3C)>NW0*K,"AW8]/N.R^)6-(.0:W9HJ42]P"E782Y]4],8:V($Q\/ M!,S)1UKR!!$G4HM1G5"*D7)KW"(L\GM8[9\8J=HU2N!H+#(K0]1O%"Q*#09/ MLGM]S"@GX@<(<`)1NV0^9E#8^N/K(<4B/A!I@5OT;6P#`>8!4$,&<1,.T`:% MMA)+5N.SXUHU'M6S\A8:6(52M`5@(!`EX0<^-G6W_]+$T%0+D;SD`O[H*@NN M`9Y_@R+5H7+3R;)VJW,"G-[IGFX!G0Z<1=+3QN3FD`9>`P!#\E'F]D7C8:60 MKG5EH0T^$I0Z>?YCLV*[!#$K4G3KB['G*10;V.HKJ7Y9K!X[D"/+SG)M:@Q- M2M#HJIWDCNX90Y!KRU32![YVK0PU&''$S;'E+W,385X[JEHS9W[JK8[GL,Y= M*9('JD`'YOQ8.]7FIVH02T9:MT[FK!X;2&09Y=[E](WN#UL2/Z3($@G/\*N# M6AWMQ5O@S&O6Y`Z M->2BW2TN^?4]1NCJ`D'BW/\E15'=%@P0FG!A`190W'K.ZHDK$/\(7I)R,V^+ MTL/KZ)$NX%F=D9M`RI(&(]NK[=O^OJ:\QHC`0Y0)<4C!V!ONRFT!(UP%C@FH\;,4]E>$$H`!=<[[?V,>*O@],DI MFI<2S!-_T1]3UKI,&!?+`#):*"711@N;0IW3"`90Z&30.>EC0!8$%,C31F0@ M000K!\EN3:24%">1R`BP5+:E8(1T0C_!]KYY/KG/LY;8"7`1^[,OZ(H_1XQ, M:!;_$_JG7=+PB_E)CI=#H`)4@+Z6$BKHB9X=S3%3#[Z=4L$4P>E-%5D<86SN MX^6%(0"@\R6<[B@`<>)$@`!R"!+LM03!088$Y2AD*)`@`H,-'9ZHV"N`1HZ] M/'K